Literature DB >> 9753039

Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators.

I Papassotiriou1, J Kister, N Griffon, A Stamoulakatou, D J Abraham, M C Marden, D Loukopoulos, C Poyart.   

Abstract

Improving the delivery of oxygen to the tissues by decreasing the oxygen affinity of haemoglobin has been a major aim of several laboratories over recent years because this may reduce the consequences of anaemia and/or improve tissue oxygenation in cases of decreased blood perfusion. Within the same context, lowering the oxygen affinity may prove valuable in the application of native or recombinant haemoglobin solutions as a blood substitute. The shift of the oxygen equilibrium curve to the right is obtained by various modulators. Among them, the bezafibrate derivatives are considered as a most interesting group. These principles are of the utmost importance in thalassaemia and other haemoglobinopathies where the beneficial effects of the compensatory synthesis of fetal haemoglobin are diminished by the increased oxygen affinity of this pigment. In this paper we present the results of a study initiated to determine whether a potent oxygen affinity modifier, RSR-4, could satisfactorily decrease the oxygen affinity of fetal haemoglobin, thus improving tissue oxygenation. The experiments were carried out on whole blood and on purified haemoglobin solutions and showed that the effector markedly decreased the oxygen affinity of HbF (from 18.7 to 3.73 mmHg in whole blood). At the same time the cooperativity index (n50) and the oxygen saturation levels remained within normal limits under the conditions of the main experiment. These observations have important implications for the potential application of oxygen affinity modifiers in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753039     DOI: 10.1046/j.1365-2141.1998.00886.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Phthalides serve as potent modulators to boost fetal hemoglobin induction therapy for β-hemoglobinopathies.

Authors:  Wei-Ren Chen; Chia-Cheng Chou; Chia C Wang
Journal:  Blood Adv       Date:  2019-05-14

2.  A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.

Authors:  Xu Zhang; Binal N Shah; Wei Zhang; Santosh L Saraf; Galina Miasnikova; Adelina Sergueeva; Tatiana Ammosova; Xiaomei Niu; Mehdi Nouraie; Sergei Nekhai; Oswaldo Castro; Mark T Gladwin; Josef T Prchal; Joe G N Garcia; Roberto F Machado; Victor R Gordeuk
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

3.  Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Authors:  Victor R Gordeuk; Andrew Campbell; Sohail Rana; Mehdi Nouraie; Xiaomei Niu; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; Onyinye Onyekwere; Tatiana Ammosova; Sergei Nekhai; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

4.  Phthalide Derivatives from Angelica Sinensis Decrease Hemoglobin Oxygen Affinity: A New Allosteric-Modulating Mechanism and Potential Use as 2,3-BPG Functional Substitutes.

Authors:  Wei-Ren Chen; Youqing Yu; Muhammad Zulfajri; Ping-Cheng Lin; Chia C Wang
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 5.  Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Authors:  Victor R Gordeuk; Nigel S Key; Josef T Prchal
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

6.  Non-thermal radio frequency and static magnetic fields increase rate of hemoglobin deoxygenation in a cell-free preparation.

Authors:  David Muehsam; Parviz Lalezari; Rukmani Lekhraj; Provvidenza M Abruzzo; Provvidenza Abruzzo; Alessandra Bolotta; Marina Marini; Ferdinando Bersani; Giorgio Aicardi; Arthur Pilla; Diana Casper
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.